PKI News and Press, PerkinElmer Inc. From 11/14/22

The US FDA has granted approval to PerkinElmer's ( NYSE: PKI ) EONIS SCID-SMA assay kit for in vitro diagnostic (IVD) use for spinal muscular atrophy ( SMA ) and severe combined immunodeficiency ( SCID ) in newborns. The platform uses PCR technology to screen f...

Building on its contributions to newborn screening globally, PerkinElmer’s latest FDA authorized assay enables the simultaneous detection of SMA and SCID PerkinElmer Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced t...

PerkinElmer Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced that the Company will present at the 2022 Stifel Healthcare Conference on Wednesday, November 16, 2022 at 9:10 a.m. ET in New York, NY. Max Krakowiak, senior vice preside...

PerkinElmer, Inc. (PKI) Q3 2022 Earnings Conference Call November 8, 2022 8:00 AM ET Company Participants Steve Willoughby - Senior Vice President, Investor Relations Prahlad Singh - President and Chief Executive Officer Max Krakowiak - Senior Vice President and ...

The following slide deck was published by PerkinElmer, Inc. in conjunction with their 2022 Q3 earnings call. For further details see: PerkinElmer, Inc. 2022 Q3 - Results - Earnings Call Presentation

PerkinElmer press release ( NYSE: PKI ): Q3 Non-GAAP EPS of $1.51 beats by $0.03 . Revenue of $1.03B (-12.0% Y/Y) misses by $10M . Pro forma adjusted operating profit margin was 26.3% as a percentage of adjusted revenue, as compared to 30.8% in the same period ...

Third quarter revenue of $712 million; (17)% reported growth Pro forma* total revenue of $1,033 million; 9% pro forma non-COVID organic growth Third quarter GAAP EPS from continuing operations of $0.55; pro forma adjusted EPS of $1.51 Initiates fourth quarter...

Highlights include increasing commitment to further reduce Scope 1 & 2 emissions and becoming a signatory of the United Nations Global Compact PerkinElmer Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today released its 2022 Envir...

EPIC SCIENCES EXPANDS EXECUTIVE TEAM AND WELCOMES NEW CHIEF FINANCIAL OFFICER IN PREPARATION FOR RAPID GROWTH PR Newswire Bill Kullback Brings Proven Track Record of Scaling Companies for Successful Outcomes SAN DIEGO , Nov. 1, 2022 /PRNewswire/ -...

PerkinElmer ( NYSE: PKI ) expects its Q3 organic revenue growth, non-COVID organic revenue growth and adjusted earnings per share to exceed its prior guidance. In its Q2 earnings release , the company guided for Q3 revenue of ~$1.02-1.03B and adj. EPS of $1.40-1.45. It...